Agilent Technologies (NYSE:A – Get Rating) announced its quarterly earnings data on Monday. The medical research company reported $1.53 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.39 by $0.14, MarketWatch Earnings reports. Agilent Technologies had a net margin of 18.31% and a return on equity of 30.55%. The firm had revenue of $1.85 billion during the quarter, compared to analyst estimates of $1.76 billion. During the same quarter in the prior year, the firm posted $1.21 earnings per share. Agilent Technologies’s quarterly revenue was up 11.4% on a year-over-year basis. Agilent Technologies updated its Q1 guidance to $1.29-$1.31 EPS and its FY23 guidance to $5.61-$5.69 EPS.
Agilent Technologies Trading Up 8.1 %
NYSE:A opened at $156.86 on Wednesday. Agilent Technologies has a 12-month low of $112.52 and a 12-month high of $162.62. The firm has a market cap of $46.44 billion, a PE ratio of 37.62, a price-to-earnings-growth ratio of 2.65 and a beta of 1.06. The company has a current ratio of 1.94, a quick ratio of 1.41 and a debt-to-equity ratio of 0.54. The stock has a fifty day moving average price of $133.55 and a 200 day moving average price of $128.29.
Agilent Technologies Increases Dividend
The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, January 25th. Stockholders of record on Tuesday, January 3rd will be given a dividend of $0.225 per share. The ex-dividend date of this dividend is Friday, December 30th. This represents a $0.90 dividend on an annualized basis and a dividend yield of 0.57%. This is a positive change from Agilent Technologies’s previous quarterly dividend of $0.21. Agilent Technologies’s dividend payout ratio is currently 20.14%.
Insiders Place Their Bets
Hedge Funds Weigh In On Agilent Technologies
A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Penserra Capital Management LLC acquired a new position in Agilent Technologies in the first quarter valued at $60,000. Covestor Ltd grew its stake in Agilent Technologies by 171.0% during the 1st quarter. Covestor Ltd now owns 1,241 shares of the medical research company’s stock worth $164,000 after buying an additional 783 shares during the last quarter. Brown Brothers Harriman & Co. increased its position in Agilent Technologies by 169.5% during the first quarter. Brown Brothers Harriman & Co. now owns 1,237 shares of the medical research company’s stock worth $164,000 after buying an additional 778 shares during the period. Geller Advisors LLC lifted its stake in Agilent Technologies by 18.5% in the first quarter. Geller Advisors LLC now owns 1,602 shares of the medical research company’s stock valued at $212,000 after buying an additional 250 shares during the last quarter. Finally, Atria Wealth Solutions Inc. acquired a new stake in shares of Agilent Technologies in the second quarter valued at approximately $219,000.
Wall Street Analyst Weigh In
A number of brokerages have recently issued reports on A. KeyCorp raised their price target on shares of Agilent Technologies from $155.00 to $165.00 and gave the stock an “overweight” rating in a report on Tuesday. Cowen upped their price target on Agilent Technologies from $160.00 to $168.00 in a research note on Tuesday. Credit Suisse Group assumed coverage on Agilent Technologies in a research report on Wednesday, August 24th. They set an “outperform” rating and a $165.00 price objective for the company. StockNews.com began coverage on shares of Agilent Technologies in a research report on Wednesday, October 12th. They issued a “strong-buy” rating on the stock. Finally, SVB Leerink lifted their price target on shares of Agilent Technologies from $145.00 to $160.00 and gave the company an “outperform” rating in a research report on Tuesday. Four research analysts have rated the stock with a hold rating, nine have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, Agilent Technologies currently has a consensus rating of “Moderate Buy” and a consensus target price of $157.00.
Agilent Technologies Company Profile
Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; vacuum pumps, and measurement technologies.
- Get a free copy of the StockNews.com research report on Agilent Technologies (A)
- After Nixing its 13% Dividend, Is Lumen Technologies Okay To Own?
- The Sell-Side Caps Gains In Dick’s Sporting Goods
- Cisco Systems Hopes Restructuring Cuts Costs to Drive Revenue
- Want to Get a 10% Dividend Yield, Look Here
- Stock-ing Stuffers: 3 Attractive Stocks Trading Around $10
Receive News & Ratings for Agilent Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agilent Technologies and related companies with MarketBeat.com's FREE daily email newsletter.